The molecular mechanism of HDAC inhibitors in anticancer effects - PubMed (original) (raw)
Affiliations
- PMID: 16978537
Free article
Review
The molecular mechanism of HDAC inhibitors in anticancer effects
Gaofeng Bi et al. Cell Mol Immunol. 2006 Aug.
Free article
Abstract
HDACs and HATs are two kinds of enzymes which catalyse deacetylation and acetylation of histone in eukaryotes, whose dynamic balance has accurate regulation for gene transcription and gene expression of eukaryotes at DNA level. Disbalance of them can bring the disorder of proliferation and differentiation in normal cells, and then lead to the initiation of tumor. Their aberrant functions were directly related to the initiation and progression of various tumors, such as promyelocytic leukemia, Hodgkin lymphoma, colonic cancer and gastral cancer. The inhibitors of HDACs are used for treatment of tumor. They can restrain the activity of HDACs and block the inhibition of gene expression caused by the disorder of deacetylation. Its major biological effects lie in inducing differentiation of tumor cells, arresting cell circle at G0/G1, activating cell apoptosis gene, enhancing the sensitivity of chemical therapy and radioactive therapy. So far HDAC has been an important target enzyme in anticancer drug research.
Similar articles
- Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Mai A, et al. Med Res Rev. 2005 May;25(3):261-309. doi: 10.1002/med.20024. Med Res Rev. 2005. PMID: 15717297 Review. - HDAC inhibitors for the treatment of cancer.
Secrist JP, Zhou X, Richon VM. Secrist JP, et al. Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Curr Opin Investig Drugs. 2003. PMID: 14763127 Review. - Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A, Budillon A. Di Gennaro E, et al. Amino Acids. 2004 Jul;26(4):435-41. doi: 10.1007/s00726-004-0087-3. Epub 2004 Jun 11. Amino Acids. 2004. PMID: 15290351 Review. - Development of histone deacetylase inhibitors for cancer treatment.
Marchion D, Münster P. Marchion D, et al. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583. Expert Rev Anticancer Ther. 2007. PMID: 17428177 Review. - Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S, Ho AD, Mahlknecht U. Mei S, et al. Int J Oncol. 2004 Dec;25(6):1509-19. Int J Oncol. 2004. PMID: 15547685 Review.
Cited by
- Recent Advances and Challenges in Uveal Melanoma Immunotherapy.
Fu Y, Xiao W, Mao Y. Fu Y, et al. Cancers (Basel). 2022 Jun 23;14(13):3094. doi: 10.3390/cancers14133094. Cancers (Basel). 2022. PMID: 35804863 Free PMC article. Review. - New Treatment Horizons in Uveal and Cutaneous Melanoma.
Brănişteanu DE, Porumb-Andrese E, Porumb V, Stărică A, Moraru AD, Nicolescu AC, Zemba M, Brănişteanu CI, Brănişteanu G, Brănişteanu DC. Brănişteanu DE, et al. Life (Basel). 2023 Jul 31;13(8):1666. doi: 10.3390/life13081666. Life (Basel). 2023. PMID: 37629523 Free PMC article. Review. - Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K, Yamagata T, Mitani K. Sasaki K, et al. Cancer Sci. 2008 Feb;99(2):414-22. doi: 10.1111/j.1349-7006.2007.00699.x. Cancer Sci. 2008. PMID: 18271940 Free PMC article. - Recent Advances in Molecular and Genetic Research on Uveal Melanoma.
Fuentes-Rodriguez A, Mitchell A, Guérin SL, Landreville S. Fuentes-Rodriguez A, et al. Cells. 2024 Jun 12;13(12):1023. doi: 10.3390/cells13121023. Cells. 2024. PMID: 38920653 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical